1-(2,4-dimethylphenyl)-4-methylpiperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(2,4-dimethylphenyl)-4-methylpiperazine
• 化学式: C₁₃H₂₀N₂
• 分子量: 204.315
• InChiKey: GBYHLLBCDBFCPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-甲基哌嗪 、 2,4-二甲基溴苯 在 间三联苯 、 palladium diacetate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.17h， 生成 1-(2,4-dimethylphenyl)-4-methylpiperazine
  参考文献：
  名称：

  Role of the Base in Buchwald–Hartwig Amination

  摘要：

  The BuchwaldHartwig amination has been investigated theoretically and experimentally to examine the scope of possible bases under different reaction conditions. Nonpolar solvents resist the formation of new charges. Therefore, the base should be anionic to be able to deprotonate the neutral palladiumamine complex and/or expel the anionic leaving group (bromide). The calculated barrier for the organic base DBU was found to be prohibitively high. In polar solvent, dissociation of bromide becomes possible, but here the base will instead form a complex with palladium, creating an overly stable resting state. The conclusions for both solvent classes hold for both a hindered monodentate phosphine and the labile bidentate ligand BINAP. The computational studies were supported by experimental testing of a range of bases using BINAP in two different solvents, toluene and DMF.

  DOI：

  10.1021/jo501817m

文献信息

• ANTHRANILAMIDE INHIBITORS OF AURORA KINASE
  申请人：Johnson Neil W.

  公开号：US20080182852A1

  公开（公告）日：2008-07-31

  The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R 1 , R 2 , R 3 , R 4 , r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

  本发明涉及以下公式所代表的化合物： 或其药学上可接受的盐； 其中R1、R2、R3、R4、r和s如前所定义。本发明的化合物在治疗与Aurora激酶活性相关的疾病，如癌症方面是有用的。
• Aryl-Diadamantyl Phosphine Ligands in Palladium-Catalyzed Cross-Coupling Reactions: Synthesis, Structural Analysis, and Application
  作者：Ádám Sinai、Dániel Cs. Simkó、Fruzsina Szabó、Attila Paczal、Tamás Gáti、Attila Bényei、Zoltán Novák、András Kotschy

  DOI：10.1002/ejoc.201901834

  日期：2020.3.8

  Bulky diadamantyl aryl phoshine ligands were synthesized and utilized in Buchwald‐Hartwig coupling reactions of sterically demanding ortho‐substituted aryl chlorides. The ligands also showed enhanced catalytic activity in the coupling of tosyl hydrazones and aryl halides.

  合成了大体积的二金刚烷基芳基膦配体，并将其用于空间要求的邻位取代的芳基氯化物的Buchwald-Hartwig偶联反应中。在甲苯磺酰also和芳基卤化物的偶联中，配体还显示出增强的催化活性。
• N-(3,4-disubstituted phenyl) salicylamide derivatives
  申请人：TOKUYAMA Ryukou

  公开号：US20080227784A1

  公开（公告）日：2008-09-18

  A compound represented by the following formula (I) or a salt thereof: wherein R 1 , R 2 , R 3 and R 4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C 1-4 alkyl group, a halogenated C 1-4 alkyl group or a C 1-4 alkoxy group, R 5 represents a halogen atom, cyano group, a C 1-4 alkyl group, a halogenated C 1-4 alkyl group or a C 1-4 alkoxy group, R 6 represents a C 5-7 cycloalkyl group, a substituted C 5-7 cycloalkyl group, a 5 to 7-membered completely saturated heterocyclic group or a substituted 5 to 7-membered completely saturated heterocyclic group, X represents a single bond, oxygen atom, sulfur atom, NR 7 , —O—CH 2 — or —N(R 8 )—CH 2 —, R 7 represents hydrogen atom or a C 1-4 alkyl group, or R 7 may combine with a substituent of R 6 to represent a single bond, methylene group or ethylene group, R 8 represents hydrogen atom, a C 1-4 alkyl group or a C 7-12 aralkyl group, which is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of diseases caused by an activation of STAT6 and/or NF-κB.

  由以下式（I）表示的化合物或其盐：其中R1、R2、R3和R4代表氢原子、卤原子、氰基、硝基、C1-4烷基、卤代C1-4烷基或C1-4烷氧基，R5代表卤原子、氰基、C1-4烷基、卤代C1-4烷基或C1-4烷氧基，R6代表C5-7环烷基、取代的C5-7环烷基、5至7-成员完全饱和杂环基或取代的5至7-成员完全饱和杂环基，X代表单键、氧原子、硫原子、NR7、—O—CH2—或—N(R8)—CH2—，R7代表氢原子或C1-4烷基，或R7可以与R6的取代基结合以表示单键、亚甲基基团或乙烯基团，R8代表氢原子、C1-4烷基或C7-12芳基烷基，可用作药物的活性成分，用于预防和/或治疗由STAT6和/或NF-κB激活引起的疾病。
• IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF
  申请人：IMPACT THERAPEUTICS, INC.

  公开号：US20200131192A1

  公开（公告）日：2020-04-30

  Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R 1 -R 5 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

  本文揭示了咪唑[1,2-b]嘧啶并[4,5-d]吡啶嗪-5(6H)-酮化合物，具体由公式I表示：或其药用可接受的盐或前药，其中A和R1-R5在此定义。具有公式I的化合物是Wee1激酶抑制剂。因此，本公开的化合物可用于治疗由异常Wee1活性引起的疾病。
• [EN] PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR<br/>[FR] DÉRIVÉ DE PYRAZOLO[3,4-D]PYRIMIDINE-3-CÉTONE UTILISÉ EN TANT QU'INHIBITEUR DE WEE-1<br/>[ZH] 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物
  申请人：WIGEN BIOMEDICINE TECH SHANGHAI CO LTD

  公开号：WO2021254389A1

  公开（公告）日：2021-12-23

  本发明涉及一种如通式(1)所示的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，以及包含其的药物组合物，其制备方法和其作为Wee-1抑制剂在抗肿瘤药物制备中的用途。(1)